Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Phase II Study on Voriconazole for Treatment of Chinese Patients with Malignant Hematological Disorders and Invasive Aspergillosis

  • Zhang, Xue-Zhong (Hematology Department of Nanjing First Hospital, Nanjing Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, JiangSu Cancer Hospital and Research Institute) ;
  • Xu, Yan-Li (Hematology Department of Nanjing First Hospital, Nanjing Medical University) ;
  • Zhang, Xiu-Qun (Hematology Department of Nanjing First Hospital, Nanjing Medical University) ;
  • Su, Ai-ling (Hematology Department of Nanjing First Hospital, Nanjing Medical University) ;
  • Shen, Zheng-Shan (Hematology Department of Nanjing First Hospital, Nanjing Medical University)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate the efficacy and safety of voriconazole in treating Chinese patients with hematological malignancies and invasive aspergillosis. Methods: From March 2007 to April 2012, patients with diagnoses confirmed by CT, GM test and/or PCR assays, were recruited into this study. Aspergillosis of all patients were treated with voriconazole 6 mg/kg intravenous infusion (iv) every 12 h for 1 day, followed by 4 mg/kg IV every 12 h for 10-15 days; Then, switch to oral administration that was 200mg every 12h for 4-12 weeks. Efficacy and safety were evaluated according to Practice Guideline of Infectious Diseases Society of America. Results: The overall response rate of 38 patients after voriconazole treatment was 81.6%. The median time to pyretolysis was 4.5 days. Treatment related side effects were mild and found in only 15.8% of cases. No treatment related deaths occurred. Conclusions: Voriconazole can considered to be a safe and effective front-line therapy to treat patients with hematological malignancies and invasive aspergillosis. Alternatively it could be used as a remedial treatment when other antifungal therapies are ineffective.

Keywords

References

  1. Baddley JW, Andes DR, Marr KA, et al (2012). Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol. 2012 Jun 11.
  2. Egerer G, Reichert D, Pletz MW, et al (2012). Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry. Eur J Med Res, 17, 7. https://doi.org/10.1186/2047-783X-17-7
  3. Herbrecht R, Denning DW, Patterson TF, et al (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, 408-15. https://doi.org/10.1056/NEJMoa020191
  4. Hilde VC, Sophie M, Marie-Paule D, et al (2008). Voriconazole treatment of invasive aspergillosis. Clin Drug Invest, 28, 509-21. https://doi.org/10.2165/00044011-200828080-00006
  5. Hoenigl M, Strenger V, Buzina W, et al (2012). European Organization for the Research and Treatment of Cancer/ Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother. published online on May 7, 2012 and accessed on Jun 2nd, 2012.
  6. Horbrecht R, Letscher-Bru V, Oprea C, et al (2002). Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol, 20, 1898-906. https://doi.org/10.1200/JCO.2002.07.004
  7. Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
  8. Huang XE, Li CG, Li Y, et al (2011). European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. Asian Pac J Cancer Prev, 12, 2797-800.
  9. Georgiadou SP, Kontoyiannis DP, et al (2012). Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis? J Infect. 2012 May 9.
  10. Godet C, Elsendoorn A, Roblot F, et al (2012). Benefit of CT scanning for assessing pulmonary disease in the immunodepressed patient. Diagn Interv Imaging, 93, 425-30. https://doi.org/10.1016/j.diii.2012.04.001
  11. Gong P, Huang XE, Chen CY, et al (2012). Comparison on complications of peripherally inserted central catheters by ultrasound guide or conventional method in cancer patients. Asian Pac J Cancer Prev, in press.
  12. Hadrich I, Makni F, Neji S, et al (2012). Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Med Mycol. 2012 May 15.
  13. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pacific J Cancer Prev, 11, 1059-62.
  14. Kriengkauykiat J, Ito JI, Dadwal SS (2011). Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol, 3, 175-91.
  15. Li CG, Huang XE, Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  16. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  17. Mengoli C, Cruciani M, Barnes RA, et al (2009). Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis, 9, 89-96. https://doi.org/10.1016/S1473-3099(09)70019-2
  18. Metzke B, Neubauer WC, Hieke S, et al (2012). Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysis. Pharmacoepidemiol Drug Saf. published online on 2012 May 28. doi: 10.1002/pds.3278, and accessed on Jun 2nd, 2012.
  19. Miller MA, DiNunzio J, Matteucci ME, et al (2012). Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm, 38, 557-70. https://doi.org/10.3109/03639045.2011.616513
  20. Misra R, Malik A, Singhal S (2011). Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species. Indian J Pathol Microbiol, 54, 112-6. https://doi.org/10.4103/0377-4929.77352
  21. Nicolle MC, Bénet T, Thiebaut A, et al (2011). Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 96, 1685-91. https://doi.org/10.3324/haematol.2011.044636
  22. Ohba H, Miwa S, Shirai M, et al (2012). Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med, 106, 724-9. https://doi.org/10.1016/j.rmed.2012.01.014
  23. Reinwald M, Spiess B, Heinz WJ, et al (2012). Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol. 2012 Jun 1. doi: 10.1111/j.1600-0609.2012.01806.x.
  24. Sambatakou H, Dupont B, Lode H, et al (2006). Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med, 119, 527.e17-24. https://doi.org/10.1016/j.amjmed.2005.11.028
  25. Schwartz S, Reisman A, Troke PF (2011). The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection, 39, 201-10. https://doi.org/10.1007/s15010-011-0108-6
  26. Springer J, Schloßnagel H, Heinz W, et al (2012). A novel extraction method combining plasma with whole blood fraction shows excellent sensitivity and reproducibility in patients at high risk for invasive aspergillosis. J Clin Microbiol. 2012 May 16.
  27. Stefan S, Markus R, Patricia R, et al (2005). Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood, 106, 2641-5. https://doi.org/10.1182/blood-2005-02-0733
  28. Stopiglia CD, Arechavala A, Carissimi M, et al (2012). Standardization and characterization of antigens for the diagnosis of aspergillosis. Can J Microbiol, 58, 455-62. https://doi.org/10.1139/w2012-013
  29. Tabarsi P, Soraghi A, Marjani M, et al (2012). Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant, 10, 278-81. https://doi.org/10.6002/ect.2011.0176
  30. Wang ZY, Cai JP, Qiu LW, et al (2012). Development of monoclonal antibody-based galactomannoprotein antigencapture ELISAs to detect Aspergillus fumigatus infection in the invasive aspergillosis rabbit models. Eur J Clin Microbiol Infect Dis. 2012 Jun 5.
  31. White PL, Bretagne S, Klingspor L, et al (2010). Aspergillus PCR: one step closer to standardization. J Clin Microbiol, 48, 1231-40. https://doi.org/10.1128/JCM.01767-09
  32. Wingard JR, Carter SL, Walsh TJ, et al (2010). Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 116, 5111-8. https://doi.org/10.1182/blood-2010-02-268151
  33. Yan PW, Huang XE, Jiang Y, et al (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
  34. Yuan X, Wang R, Bai CQ, et al(2012). Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials. Pharmazie, 67, 267-73.
  35. Yu DS, Huang XE, Zhou JN (2012). A comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, in press.
  36. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer vol.13, pp.11, 2012, https://doi.org/10.7314/APJCP.2012.13.11.5587
  2. Comparative Study on Transcatheter Arterial Chemoembolization, Portal Vein Embolization and High Intensity Focused Ultrasound Sequential Therapy for Patients vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6257
  3. ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6523
  4. Effect of Portal Vein Chemotherapy on Liver Metastasis after Surgical Resection of Colorectal Cancer vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4699
  5. Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4757
  6. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  7. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  8. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  9. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  10. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1703
  11. Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2005
  12. (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2009
  13. Phase II Study of Pemetrexed as Second or Third Line Combined Chemotherapy in Patients with Colorectal Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2019
  14. ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2591
  15. Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2611
  16. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  17. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  18. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  19. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  20. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  21. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  22. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  23. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  24. Pulmonary fungal infections- recent updates vol.3, pp.4, 2014, https://doi.org/10.1007/s13665-014-0089-x